Literature DB >> 3162848

HPLC analysis of doxorubicin, epirubicin and fluorescent metabolites in biological fluids.

C M Camaggi1, R Comparsi, E Strocchi, F Testoni, F Pannuti.   

Abstract

A specific, sensitive and reliable HPLC method for the determination of doxorubicin (DX), epirubicin (epiDX) and their known fluorescent metabolites [doxorubicinol (DXol), epirubicinol (epiDXol) 7-deoxy-adriamycinone (metabolite C), adriamycinone (metabolite D), 7-deoxy-13-dihydro-adriamycinone (metabolite E), 13-dihydro-adriamycinone (metabolite F), 4'-O-beta-D-glucuronyl-4'-epiDX (metabolite G) and 4'-O-beta-D-glucuronly 13-dihydro-4'-epiDX (metabolite H)] in biological fluids (human plasma, bile and urine) has been developed and tested. Plasma samples were solid-phase-extracted (C18-bonded silica cartridges). Urine and bile samples were injected directly after the addition of the internal standard and dilution with 0.3 M phosphoric acid. Complete separation of unchanged drugs and metabolites was achieved with a mobile phase consisting of 75.6% 10 mM KH2PO4 and 24.4% CH3CN (the pH of the solution was adjusted to 4.3 with 0.03 M H3PO4) at a flow rate of 1.5 ml/min. For the analyses we used a cyanopropyl chromatographic column (25 cm x 4.6 mm i.d.; particle size 5 micron) and fluorescence detection with excitation wavelength set at 470 nm and emission at 580 nm. Sensitivity was better than 0.3 ng/ml for all substances analysed. The mean absolute recovery of unchanged drugs and metabolites was between 88.3% (metabolite E) and 98.92% (metabolite G). Intra- and interassay precisions (plasma samples) were better than 10.6% and 13.0%.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3162848     DOI: 10.1007/bf00262773

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  11 in total

1.  Synthesis and antitumor properties of new glycosides of daunomycinone and adriamycinone.

Authors:  F Arcamone; S Penco; A Vigevani; S Redaelli; G Franchi; A DiMarco; A M Casazza; T Dasdia; F Formelli; A Necco; C Soranzo
Journal:  J Med Chem       Date:  1975-07       Impact factor: 7.446

2.  Quantitative determination of low concentrations of adriamycin in plasma and cell cultures, using a volatile extraction buffer.

Authors:  M A Van Lancker; L A Bellemans; A P De Leenheer
Journal:  J Chromatogr       Date:  1986-01-24

3.  Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.

Authors:  C M Camaggi; E Strocchi; V Tamassia; A Martoni; M Giovannini; G Lafelice; N Canova; D Marraro; A Martini; F Pannuti
Journal:  Cancer Treat Rep       Date:  1982-10

4.  Determination of 4'-epidoxorubicin and its 13-dihydro derivative in human plasma by high-performance liquid chromatography with fluorescence detection.

Authors:  E Moro; M G Jannuzzo; M Ranghieri; S Stegnjaich; G Valzelli
Journal:  J Chromatogr       Date:  1982-06-11

5.  Simplified toxicologic monitoring of adriamycin, its major metabolites and nogalamycin by reverse-phase high pressure liquid chromatography, Part I: Analytical techniques for isolated human plasma.

Authors:  A J Quattrone; D F Ranney
Journal:  J Anal Toxicol       Date:  1980 Jan-Feb       Impact factor: 3.367

6.  Improved high-performance liquid chromatography assay of doxorubicin: detection of circulating aglycones in human plasma and comparison with thin-layer chromatography.

Authors:  D E Brenner; S Galloway; J Cooper; R Noone; K R Hande
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

7.  Measurement of adriamycin (doxorubicin) and its metabolites in human plasma using reversed-phase high-performance liquid chromatography and fluorescence detection.

Authors:  R N Pierce; P I Jatlow
Journal:  J Chromatogr       Date:  1979-12-01

8.  Reversed-phase liquid chromatographic determination of plasma levels of adriamycin and adriamycinol.

Authors:  S Eksborg; H Ehrsson; I Andersson
Journal:  J Chromatogr       Date:  1979-12-01

9.  Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.

Authors:  C M Camaggi; R Comparsi; E Strocchi; F Testoni; B Angelelli; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

10.  Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function.

Authors:  R S Benjamin; C E Riggs; N R Bachur
Journal:  Cancer Res       Date:  1977-05       Impact factor: 12.701

View more
  5 in total

1.  Epirubicin metabolism and pharmacokinetics after conventional- and high-dose intravenous administration: a cross-over study.

Authors:  C M Camaggi; E Strocchi; P Carisi; A Martoni; B Melotti; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

2.  Epirubicin and doxorubicin comparative metabolism and pharmacokinetics. A cross-over study.

Authors:  C M Camaggi; R Comparsi; E Strocchi; F Testoni; B Angelelli; F Pannuti
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  HPLC Method Development for Quantification of Doxorubicin in Cell Culture and Placental Perfusion Media.

Authors:  Mansi Shah; Luke Bourner; Shariq Ali; Sanaalarab Al-Enazy; Menatallah M Youssef; Morgan Fisler; Erik Rytting
Journal:  Separations       Date:  2018-01-24

4.  Silk Fibroin-Coated Nanoagents for Acidic Lysosome Targeting by a Functional Preservation Strategy in Cancer Chemotherapy.

Authors:  Mixiao Tan; Weiwei Liu; Fengqiu Liu; Wei Zhang; Hui Gao; Juan Cheng; Yu Chen; Zhigang Wang; Yang Cao; Haitao Ran
Journal:  Theranostics       Date:  2019-01-25       Impact factor: 11.556

5.  Rapid and sensitive determination of doxorubicin in human whole blood by vertically-ordered mesoporous silica film modified electrochemically pretreated glassy carbon electrodes.

Authors:  Meifang Wang; Jing Lin; Jiawei Gong; Mingchen Ma; Hongliang Tang; Jiyang Liu; Fei Yan
Journal:  RSC Adv       Date:  2021-03-01       Impact factor: 3.361

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.